Skip to main content

Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)

Terminated · Phase 3 · NCT01247207

Conditions: Duchenne Muscular Dystrophy

At a glance

Research payments reported, 2025
$498,899
U.S. investigators named
27
Sites paid
27
Planned or actual enrollment
265

About the trial

Sponsor
PTC Therapeutics
Tested
Ataluren (drug)
Dates
Started 2010-11-22; completion 2026-02-10
Results posted
Yes

The objective of this study is to assess the safety and tolerability of 10, 10, 20 milligrams per kilogram (mg/kg) ataluren in participants with nmDBMD who had prior exposure to ataluren in a PTC sponsored clinical trial or treatment plan, and siblings of those participants (provided those participants have completed the placebo-controlled portion of the trial). The treatment will continue under this protocol until consent withdrawal by participants, withdrawal due to worsen condition after initiating ataluren treatment, withdrawal by investigator, withdrawal due to participant unable to tolerate ataluren, participant is eligible to participate in another ataluren nmDBMD clinical trial pr…

From ClinicalTrials.gov, last updated 2026-10-08. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Ptc Therapeutics, Inc. reported $498,899 in research payments for this study in 2025 (248 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.